Revenue
0 USD
2020 Q3 · USD
Exact inputs and evidence
- Revenue: 0 USD Source
Fundies. English
Nugenerex Immuno-oncology, Inc.
EDGAR10 filing records in this dataset, filed from 2020-06-17 to 2021-06-14. Reported financial figures are available; chart coverage varies by period.
Holdings and insider activity
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.
No Form 3, 4 or 5 for this issuer is in the store. The store has read filings dated 2004-06-14 to 2026-10-26; this is not a statement that none were filed.
Latest quarter
- Cash and cash equivalents
- Not available
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 100 million shares Source
Exact value
100300000 shares
Reported share-count change
-74.93% · -300 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Net income
-6.22 million USD
2020-05-01 – 2021-04-30
Exact inputs and evidence
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2021-06-14.
Financial data available through: 2020-07-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 2 of 11 periods available· newest 2020-07-31
- Net income: 2 of 11 periods available· newest 2020-07-31
- operating cash flow: No compatible figures in this window
- capital expenditure: No compatible figures in this window
- Total assets: 2 of 11 periods available· newest 2020-07-31
- liabilities: No compatible figures in this window
- Current assets: 2 of 11 periods available· newest 2020-07-31
- Current liabilities: 2 of 11 periods available· newest 2020-07-31
- cash and cash equivalents: No compatible figures in this window
- long term debt: No compatible figures in this window
- Shares outstanding: 2 of 11 periods available· newest 2020-07-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 415,794Prior period
−USD 1.11 million
–
Current period
−USD 1.52 million
–
Exact inputs and evidence
-1523810 − -1108016 = -415794 USD
-1108016 USD · 2018-08-01 – 2019-07-31
Inspect prior input Prior source-1523810 USD · 2019-08-01 – 2020-07-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Operating cash flow, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2019 2018-08-01 – 2019-07-31 | −USD 1.11 million Exact valueExact value: -1108016 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Operating cash flow + Capital expenditure is unavailable for this period. |
| 2020 2019-08-01 – 2020-07-31 | −USD 1.52 million Exact valueExact value: -1523810 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Operating cash flow + Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
10 filings · 278 latest values · 278 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001804585, 1804585, edgar:1804585
Also known as NUGENEREX IMMUNO-ONCOLOGY, INC., Nugenerex Immuno-oncology, Inc.